Compare PAHC & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAHC | PGEN |
|---|---|---|
| Founded | 1946 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2014 | 2013 |
| Metric | PAHC | PGEN |
|---|---|---|
| Price | $48.49 | $3.52 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $34.33 | $7.67 |
| AVG Volume (30 Days) | 232.7K | ★ 4.7M |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | ★ 1883.33 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $833,350,000.00 | $230,981,000.00 |
| Revenue This Year | $17.03 | $342.78 |
| Revenue Next Year | $3.82 | $478.46 |
| P/E Ratio | $36.22 | ★ N/A |
| Revenue Growth | ★ 4.12 | N/A |
| 52 Week Low | $16.16 | $1.11 |
| 52 Week High | $56.30 | $5.47 |
| Indicator | PAHC | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 47.64 | 38.32 |
| Support Level | $37.09 | $3.49 |
| Resistance Level | $56.14 | $5.10 |
| Average True Range (ATR) | 2.27 | 0.29 |
| MACD | -0.94 | -0.09 |
| Stochastic Oscillator | 26.88 | 14.68 |
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.